Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of MMH-407 in the Treatment of Acute Respiratory Viral Infection
Phase: PHASE3
Conditions: Viral Respiratory Infection
Sponsor: Materia Medica Holding

 
 
 
 
 
 
 
 
 
 
 
 
Multicenter double-blind placebo-controlled parallel group 
randomized clinical trial of efficacy and safety of MMH-407 in the 
treatment of acute respiratory viral infection 
 
 
 
 
 
Phase III 
 
 
 
 
 
 
 
 
 
 
Sponsor 
OOO «NPF «MATERIA MEDICA HOLDING» 
Protocol number 
MMH-407-001 
Version date: 
July 01, 2019 
ClinicalTrials.gov Id: 
NCT04244084 
 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 2 of 14 
Protocol Summary 
 
This document represents the protocol summary for the study on human patients. The study will 
be carried out in accordance with ICH GCP, National Standard of the Russian Federation GOST 
52379-2005 "Good Clinical Practice", Helsinki Declaration of World Medical Association, 
relevant requirements of the regulatory authorities as well as the study procedures. 
Title of Study 
Multicenter double-blind placebo-controlled parallel group randomized clinical trial of efficacy 
and safety of MMH-407 in the treatment of acute respiratory viral infection. 
Phase: III 
Sponsor: OOO "NPF "MATERIA MEDICA HOLDING", Moscow, Russia 
Protocol No. MMH-407-001 
 
Objective of the study 
 To evaluate the efficacy and safety of MMH-407 in the treatment of acute respiratory viral 
infection (ARVI). 
Endpoints  
Primary endpoint 
1. Time to resolution of ARVI symptoms1,2 (PCR-confirmed). 
Secondary endpoints 
1. Severity of ARVI (clinically diagnosed and/or PCR-confirmed); based on the area under the 
curve (AUC) data for the Total Severity (TS) score3 on days 1-6 of the observation).  
2. Percentage of patients with resolution of ARVI symptoms (clinically diagnosed and/or PCR-
confirmed).  
3. Time to resolution of ARVI symptoms (clinically diagnosed and/or PCR-confirmed).  
4. Percentage of patients with resolution of ARVI symptoms (PCR-confirmed). 
5. Dosing frequency of antipyretics on days 1-3 of therapy4.  
6. Percentage of patients requiring administration of antibiotics or hospitalization on 4-14 days of 
the observation. 
                                                 
1 Time from enrollment to symptom resolution. Resolution of ARVI symptoms is defined if body temperature ≤37.30С within 24 hours (without 
further increase during observation period) + absence/presence of ARVI symptoms ≤2. 
2 Based on a patient diary. 
3 Total Disease Index will be calculated based on the intensity of each ARVI symptom (body temperature, systemic symptoms and 
nasal/pharyngeal/chest symptoms in points) with further statistical processing of data by OOO "NPF "Materia Medica Holding" experts. To 
determine total score, absolute values of body temperature measured in Celsius degrees will be converted into relative units (or points) based on 
the following classification: ≤37.30С=0; 37.4-38.00С=1; 38.1-39.00С=2; ≥39.10С=3. 
4 Based on a patient diary. 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 3 of 14 
Safety assessment  
 Adverse events (AEs) during the therapy, AEs severity and relation to the study drug, and AEs 
outcomes.  
 Changes in vital signs during the treatment. 
 Percentage of patients with clinically relevant laboratory abnormalities. 
Study design  
Study design: multicenter, double blind, placebo-controlled, parallel group randomized clinical 
trial.  
The study will enroll outpatients of either gender aged 18-70 years old with clinical manifestations 
of ARVI within the first day after the onset of the disease during seasonal ARVI morbidity.  
After signing patient information sheet and informed consent form, medical history, thermometry, 
objective examination, laboratory tests and concomitant medication will be performed. Severity 
of ARVI symptoms is evaluated with 4-point scale. 
The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be 
performed prior to therapy to confirm the viral etiology of ARVI.  
If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1) 
he/she will be randomized into one of two groups: the 1st group will take MMH-407 according to 
the dosage regimen for 5 days; the 2nd group will take Placebo according to MMH-407 dosage 
regimen for 5 days.  
The study will use electronic patient diary for recording morning and evening axillary body 
temperature (measured using a mercury-free Geratherm Classic thermometer) and disease 
symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any 
aggravation in a patient’s condition (if applicable, for safety evaluation/AE documentation) will 
also be recorded in a patient diary. The investigator will provide instructions on filling the diary; 
at Visit 1 the patient together with a doctor will record ARVI symptom severity and body 
temperature in the diary. 
Patient will be observed for 14 days (screening, randomization - Day 1, treatment period − 5 days, 
follow-up − up to 2 days; deferred “phone visit” − Day 14). 
During the treatment and follow-up period the patients or investigators will make 3 visits and the 
fourth “phone visit” will be scheduled additionally: 1) visits by physician/patient - on Days 1, 5 
and 7 (Visits 1, 2 and 3) – in a study center or at home; 2) “phone visit” (Visit 4) – on Day 14. 
At Visits 2 and 3, the investigator will perform an objective examination, document changes in the 
symptoms and concomitant medications to check patient diaries. At Visit 3 compliance will be 
evaluated and laboratory tests will be performed. “Phone visit” is carried out to interview the 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 4 of 14 
patient about his/her condition, presence/absence of secondary bacterial/viral complications and 
use of antibiotics. 
During the study, symptomatic therapy and therapy for their co-morbidities are allowed with the 
exception of the drugs indicated in the section “Prohibited Concomitant Treatment”. 
Inclusion and exclusion criteria 
Inclusion criteria 
1. Patients of either gender aged 18-70 years. 
2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 38.0°C at 
examination + total general symptoms score ≥4, nasal/throat/chest symptoms score ≥2. 
3. The first 24 hours after ARVI onset5.  
4. Patients giving their consent to use reliable contraception during the study. 
5. Signed patient information sheet (informed consent form). 
Exclusion criteria 
1. Clinical symptoms of severe influenza/ARVI6 requiring hospitalization. 
2. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract 
infection, meningitis, sepsis, etc.) requiring administration of antibiotics from the first day of 
illness. 
3. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other 
infectious diseases, flu-like syndrome at the onset of systemic connective tissue diseases, and 
other pathology). 
4. Patients requiring antiviral medication prohibited within the study. 
5. Medical history of primary and secondary immunodeficiency. 
6. Medical history/suspicion of oncology of any localization (except for benign neoplasms). 
7. Aggravation or decompensation of chronic diseases affecting a patient's ability to participate 
in the clinical trial.  
8. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase 
deficiency, galactosemia. 
9. Allergy/ hypersensitivity to any component of the study drug.  
10. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, 
unwillingness to use contraceptive methods during the trial.  
                                                 
5 Time of ARVI onset is the time of manifestation of fever or febrile illness (axillary temperature ≥37.40С, oral or tympanic temperature 
≥37.60С, or rectal temperature ≥38.00С) 
6 Severe influenza/ARVI [7] is characterized with abrupt onset, high temperature (> 40°С) with acute intoxication symptoms (strong headache, 
body ache, insomnia, delirium, anorexia, nausea, vomiting, meningeal symptoms, sometimes encephalitic syndrome); pulse > 120 bpm, weak, 
sometimes arrhythmia; systolic blood pressure < 90 mm Hg; muffled heart sounds; respiration rate > 28/min. Very severe disease is characterized 
with fulminant presentation, rapidly developing intoxication signs, potential DIC-syndrome. 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 5 of 14 
11. Course administration of the drug products specified in the section “Prohibited Concomitant 
Therapy” within two weeks prior to inclusion in the study.  
12. Patients who will not fulfill the requirements during the study or follow the order of 
administration of the studied drug products, from the Investigator's point of view.  
13. Medical history of mental diseases, alcoholism or drug abuse that according to the 
investigator’s opinion will compromise compliance with the study procedures. 
14. Participation in other clinical trials for 3 months prior to enrollment in this study.  
15. Patients who are related to any of the on-site research personnel directly involved in the study 
or are an immediate relative of the investigator. ‘Immediate relative’ means husband, wife, 
parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted). 
16. Patients who work for OOO “NPF “MATERIA MEDICA HOLDING” (i.e. the company's 
employees, temporary contract workers, designated officials responsible for carrying out the 
research or any immediate relatives of the aforementioned). 
Criteria for Withdrawal or Termination 
1. Patient failed screening procedure.  
2. Inability or refusal of patient to comply the Protocol requirements.  
3. Deviation from the schedule of visits 2 and 3 for more than 1 day.  
4. Necessity in medicines prohibited within the study.  
5. An adverse event requiring the study drug cancellation. 
6. Desire of patient to complete the study ahead of schedule due to inefficacy of therapy or any 
other reason. 
7. Pregnancy.  
8. Cases not specified by the protocol where the investigator decides that further participation 
may harm the patient. 
9. Incorrect inclusion of ineligible patient. 
Number of patients 
It is planned to include 240 patients (120 patients in MMH-407 and Placebo groups). 
Interim analysis 
The protocol does not schedule unblinded interim analyses. At the sponsor’s decision blinded 
interim analysis may be carried out to specify population parameters and potential further 
specification of sample size (increase only).  

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 6 of 14 
Treatment 
 
Group 1 
Name of the medicinal product: MMH-407 
Active ingredient: affinity purified antibodies to human interferon gamma – 10000 UMA*, 
affinity purified antibodies to CD4 ‒ 10000 UMA*, affinity purified antibodies to β1-domain of 
MHC class II ‒ 10000 UMA*, affinity purified antibodies to β2-microglobulin of MHC class I ‒ 
10000 UMA* 
* Units of the Modifying Activity.   
 
Excipients: Lactose monohydrate – 0.267 g, microcrystalline cellulose – 0.03 g, magnesium 
stearate – 0.003 g.  
Method of administration: Tablet for oral use. One tablet per intake. On day 1, five tablets are 
taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly 
spaced during the rest of the day. From day 2 through 5, one tablet is administered three times 
daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before 
meal). The tablet should be held in mouth until complete dissolution. 
Dosage form: Tablet for oral use. 
Description: Flat, cylinder-shaped, scored beveled edge, white to off-white tablets. 
Storage conditions: At temperature below 25ºС. Keep out of the reach of children. 
Group 2 
Name of the medicinal product: Placebo 
Active ingredient: NA 
Excipients: Lactose monohydrate – 0.267 g, microcrystalline cellulose – 0.03 g, magnesium 
stearate – 0.003 g. 
Method of administration: Placebo using MMH-407 scheme.  
Dosage form: Tablet for oral use. 
Description: Flat, cylinder-shaped, scored beveled edge, white to off-white tablets. 
Storage conditions: At temperature below 25ºС. Keep out of the reach of children. 
Treatment duration 
MMH-407/Placebo treatment duration is 5 days.  
Observation period 
Overall the patient will be monitored for 14 days (screening, randomization - up to 1 day, study 
treatment period − 5 days, follow-up period − up to 2 days; delayed "phone" visit − day 14).  

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 7 of 14 
Symptomatic (Standard) treatment  
Throughout the study, the patients may receive symptomatic ARVI therapy:  
• antipyretic/non-steroidal anti-inflammatory drug (paracetamol/ibuprofen) 
and/or 
• vasoconstrictive nasal drug – oxymetazoline/naphazoline 
and/or 
• cough suppressant/expectorant drug – butamirate/ambroxol, bromhexine, guaifenesine, 
acetylcysteine. 
Indications for prescription of antipyretics:  
Increased body temperature > 39°С in patients without complications and co-morbidities and > 
38°С in patients with co-morbidities (congestive heart failure, hepatic, renal diseases; history of 
convulsive syndrome). 
If antipyretic was taken by the patient on his own (without doctor recommendation) with no 
indications the patient is not excluded from the study. The patient should record the values of 
thermometry before taking the drug, its name and dose. 
Not considered as prohibited products: 
• 
systemic antihistamines (R06A) 
• 
medication for the treatment of obstructive airway diseases (R03). 
Prohibited concomitant therapy 
Two weeks before inclusion in the study*, as well as during the study (from signing of the 
information sheet for patient /informed consent form and initiation of screening) the following 
medication are not allowed (their ATC group is indicated in brackets): 
1. 
Antivirals (J05).  
2. 
Antimicrobials and antiseptics for local treatment of oral diseases (A01AB). 
3. 
Medications for the treatment of throat diseases (R02A). 
4. 
Immunostimulants (L03), including: 
 
interferon inducers (acridonoacetic acid, meglumine acridone acetate/cycloferon®, 
umifenovir/arbidol®, kagocel®, tiloron/amixin®, polyadenyl acid + polyuridylic 
acid/poludan®, sodium oxodihydroacridinyl acetate/neovir®, lavomax®, tilaxin®, 
etc.)  
 
interferons;  

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 8 of 14 
 
bacterial immunomodulators (including ribomunyl®, sodium ribonucleate/ridostin, 
etc., sodium deoxyribonucleate/derinat®, etc., IRS-19, imudon®, broncho-munal®, 
etc.).  
 
pidotimod/immunorix;   
 
interleukins;  
 
synthetic immunostimulants (levamisole, alpha-glutamyl-tryptophan/thymogen, etc.);  
 
medication with thymus hormones.  
5. 
Non-steroidal anti-inflammatory drugs (М01, except for ibuprofen). 
6. 
Analgesics and antipyretics (N02А, N02B except for paracetamol). 
7. 
Combination preparations for symptomatic therapy of acute respiratory infections. 
8. 
Homeopathic preparations. 
9. 
Systemic (oral or parenteral) corticosteroids. 
10. 
Immunosuppressants (L04). 
11. 
Antineoplastic agents (L01) and combined (with hormones) antineoplastic endocrine 
therapy (L02). 
12. 
Immune sera and immunoglobulins (J06). 
13. 
Vaccines (J07). 
14. 
Drugs that previously caused hypersensitivity/ allergic reactions in patient. 
* Patients were allowed to take a single dose of prohibited medications (except for 9 - 14) prior to inclusion, if the 
interval between the medication intake and randomization was more than 12 hours. 
Study design scheme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schedule of study procedures  
Procedure/Visit 
Visit 1 
(Day 1) 
Visit 2 
(Day 5) 
Visit 3  
(Day 7±1) 
Visit 4 
(Day 
14±1) 
RANDOMIZATION 
Group 1: ММН-407 for 5 days + symptomatic 
therapy 
SCREENING
Visit 2 
(Day 5) 
Visit 1 
(Day 1) 
14±1 days 
Group 2: Placebo for 5 days + symptomatic therapy 
 
Visit 3  
(Day 7±1) 
Visit 4 (phone visit)  
(Day 14±1) 
STUDY 
TERMINATION 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 9 of 14 
Informed consent  
+ 
 
 
 
Registration of a study patient in the IVRS 
and assignment of patient ID 
+ 
 
 
 
Collection of complaints 
+ 
+ 
+ 
 
Medical history 
+ 
 
 
 
Physical examination 
+ 
+ 
+ 
 
ARVI symptoms registration 
+ 
+ 
+ 
 
Patient Diary  
+ 
+ 
+ 
+ 
Pregnancy test 
+ 
 
 
 
Concomitant therapy 
+ 
+ 
+ 
 
Eligibility assessment 
+ 
 
 
 
Nasopharyngeal swabs for PCR 
+ 
 
 
 
Laboratory tests* (safety evaluation) 
+ 
 
+ 
 
Randomization  
+ 
 
 
 
Study drug supply 
+ 
 
 
 
Study drug accountability and return 
 
 
+ 
 
Treatment compliance 
 
 
+ 
 
Evaluation of treatment safety 
+ 
+ 
+ 
 
Visit completion 
+ 
+ 
+ 
 
Phone survey 
 
 
 
+ 
Study completion** 
 
 
 
+ 
* Including hematology, urinalysis, biochemistry (total protein, glucose, total bilirubin, creatinine, ALT, AST, 
cholesterol). 
**In case of early withdrawal the procedure may be performed at visits 1, 2 or 3. 
 
Statistical Analyses 
SAS 9.4 will be used for data processing and statistical calculations.7 
Samples  
Total set: all patients who have signed ICF. This sample will consider all the recorded AEs, 
including those occurred prior to the study therapy. 
Safety population:  all patients who received at least one dose of the study drug. This sample will 
be used for analysis of the study treatment safety and tolerability, as all adverse events identified 
after the study drug administration will be recorded.    
Full Analysis Set. This sample includes all enrolled patients, except for those who met at least one 
of the following events: 
1) non-compliance with inclusion / exclusion criteria; 
2) the patient did not take a single dose of the study drug; 
3) lack of any data about the patient after administration of the study drug. 
This sample, the most consistent with the “Intention-to-treat” principle, will be used for 
the  Intention-to-treat analysis (ITT analysis) of the study therapy efficacy. 
                                                 
7 Licensee: OOO "NPF "Materia Medica Holding", No. 70100045 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 10 of 14 
Per protocol set. This sample includes all patients who have received the complex therapy under 
the Protocol and completed all the scheduled visits. This sample will be used for 
the Per Protocol analysis (PP- analysis) of the study therapy efficacy. The list of deviations that  
may result in complete or partial invalidity of data is developed by a medical expert jointly with a 
biostatistician according to the study design: 
1. The protocol deviations potentially resulting in partial or complete invalidation of the study 
patient's data: Violation of visit schedule. 
2. Inappropriate distribution/supply of the study drug. 
3. Prescription of prohibited therapy. 
4. ≥ 25% increase or reduction in the amount of the study therapy administered. 
5. Inability to assess the patient's compliance using the formula (e.g. loss of pack with the 
product). 
6. Major discrepancies between source documents and CRF detected during monitoring or 
another authorized check. 
7. Violation of the procedure of obtaining informed consent. 
8. Non-compliance with the clinical study protocol procedures. 
9. Inability to collect all the patient's data used for evaluation of the study endpoints 8(e.g. lack 
of entries in source documents required for verification of inclusion/exclusion criteria, safety 
and efficacy criteria). 
10. Any other protocol deviations covered by the term “major deviation”. 
Evaluation of sample size 
The sample size was assessed on the basis of the following rules and assumptions: 
1. 
Statistical provisions. 
1.1 
the power of the statistical tests “P = (1 - β )” is assumed to be 80% (the probability 
of correct rejection of the null hypothesis is 0.8); 
1.2 
the probability of a type I error “α” is allowed to be less than 5% (the probability of 
the erroneous acceptance of an alternative hypothesis is less than 0.05); 
1.3 
the statistical criteria used are 2-sided; 
1.4 
the protocol contains evaluation of minimum detectable effect at fixed: sample size, 
population variance, type 1 and 2 error values; 
1.5 
the ratio between the sample sizes of the study drug and placebo groups is 1:1 (1 
study drug patient - 1 placebo patient);  
                                                 
8 If, considering the lack of some data in primary endpoint variable, the fact of reaching the primary endpoint by the patient can still be 
determined, the patient will be eligible for PP analysis (e.g. the diary lacks some records but the time of recovery can still be determined). 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 11 of 14 
1.6 
statistical hypotheses: null and alternative hypotheses about the superiority of the 
study drug over placebo using the applied dosing regimen: 
 
H0: M1-M2 = 0 
Ha: M1-M2 ≠ 0 
where M1 – the mean time to resolution of all symptoms in the study drug group; 
M2 – the mean time to resolution of all symptoms in the placebo group. 
Analysis of the expected effect within the fixed sample will be carried out in 
accordance with the following formulas: 
n1 = kn2 
𝜺= (
(𝒛𝜶/𝟐+ 𝒛𝜷)
𝟐∗(𝟏+ 𝟏/𝒌) ∗𝝈𝟐
𝐧𝟐
)
𝟏
𝟐
 
where n1, n2 – the sample size of the study drug and the placebo groups respectively;  
ε = M1 - M2 – the minimum detectable difference in time in study drug and 
placebo groups;  
k – the coefficient of study drug /placebo sample ratio (k=1);  
ϭ – the standard deviation;  
zα/2 – a tabulated two-tailed z-test for α;  
zβ – a tabulated one-tailed z-test for β. 
1.7    effective sample size will be determined using the formula:  
Npp=NT*(1 - Cw), 
where  NT – the final sample size;  
NPP – the value calculated in section 1.6, i.e. the expected number of the 
patients completing the study per protocol;  
Cw – withdrawal coefficient. 
2. 
Assumptions about the expected effects of the clinical study: To evaluate the minimum 
detectable effect at fixed sample size a priori estimate of population parameters should be 
performed: 
A priori estimates for tested parameter variables in the groups: 
Primary endpoint (efficacy criterion): 
Time to resolution of ARVI symptoms. 
Study drug group: 
Time to resolution of symptoms was estimated on the basis of the previous studies. 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 12 of 14 
Ttr=(<max(N(2.6,1.77), N(5,1.47))>)9,10 
Where <…> stands for averaging operation, N(x,s) – normally distributed random 
variable with the mean x and standard deviation s.  
corresponds to the Gumbel type I distribution11 
for power analysis this empirical distribution is approximated by the normal distribution 
with characteristics m=5.17, σ=1.38. 
 
Note. Red area is empirical distribution of time to resolution of symptoms in Product group (number of 
simulation repetitions N=10^5). Red curve is approximate parametric distribution for the groups. 
 
Therefore, given fixed sample (Npp=120) obtained above for population standard deviation 
(sd=1.38) and levels of errors (α=0.05, β=0.2), the minimum detectable effect in the study will be 
0.71 day. When planning the study withdrawal rate of 50% patientss was taken12 (Cw=0.5). In total 
240 patients will participate in the study. 
Statistical criteria  
All the statistical calculations will be performed using two groups of statistical criteria:  
 parametric – to obtain effective evaluations for parameters of random values, if the 
relevant conditions of applicability of methods/models are not violated (e.g. sphericity, 
normality, proportionality of risks, etc.); 
 non-parametric – in any other cases. 
Parametric criteria 
                                                 
9 Based on the clinical trial “A study to assess the therapeutic efficacy and safety of Anaferon against influenza and other upper respiratory tract 
infections in aduls” [11]. Duration distributions for symptom domains are considered independent. 95% confidence interval is taken for the 
corresponding standard deviations. 
10 The data resulting in major variance evaluation are used. 
11 On the distribution of the maximum of N independent normal random variables: IID and INID cases. SDSSU Multidisciplinary Research Journal 
Vol. 1 No. 2±2013 
12 This rate is complex: 10% patients will be screening failures or will withdraw for other reasons specified in the relevant protocol section, 44% 
remaining patient will not have the diagnosis verified by PCR. 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 13 of 14 
The application of parametric criteria will be accompanied by a check of models for 
applicability (e.g. Kolmogorov-Smirnov test, Shapiro-Wilk test, etc.). 
The following parameters and approaches are to be used: 
1. To evaluate the differences of continuous variables obtained in one group at two 
different visits – Student’s test for matched samples. 
2. To evaluate the temporal dynamics of the compared indicators – analysis of variance 
(ANOVA) or covariance (ANCOVA) in the modification with repeated measures. 
3. In case of multiple comparisons between the groups will apply a variety of corrections 
for multiplicity (Dunnett, Tukey, Scheffe, Holm adaptive test), etc. 
4. In case of abnormal data distribution, approaches with the Generalized Linear Models 
and / or Mixed Linear Models will be used. 
5. Selection of the type of distribution, clarification of the factor and covariance structures 
of the model is carried out with fit statistics such as AIC (Akaike  
information criterion). 
To perform the above-mentioned statistical tests and techniques, it is assumed that the 
following SAS procedures are used:  
 
UNIVARIATE – check for normality of the compared distributions; 
 
CORR, MEANS – calculation of descriptive statistics; 
 
TTEST – Student t-test with all the modifications; 
 
GLM – analysis of Generalized Linear Models for studying temporal dynamics 
(ANOVA, ANCOVA); 
 
GENMOD – analysis of Generalized Linear Models. 
MIXED – analysis of Generalized Linear Models. 
Non-parametric criteria 
Below, there are the main types of possible comparisons with the respective criteria: 
1. To evaluate time changes in the parameters compared – Friedman test, nonparametric 
analogue of repeated measures analysis of variance. 
2. For the frequency analysis of 2×2 cross tables – χ2-test (if the compared frequencies are 
greater than 5) or Fisher exact test (if one of the compared frequencies is less than 5). 
3. For the frequency analysis of cross tables with independent strata – Cochran–Mantel–
Haenszel test (modification of the χ2-test for multiple comparisons). 
4. For the frequency analysis of data on the presence / absence of an event or outcome during 
repeated measures (cross tables with dependent strata) – survival analysis. 

Protocol No. MMH-407-001 
01-Jul-2019 
CONFIDENTIAL  
 
Page 14 of 14 
To perform the above-mentioned non-parametric statistical analysis options, it is assumed 
that the following SAS procedures are used: 
 FREQ – Friedman test, χ 2-test and / or Fisher exact test; Cochran–Mantel–Haenszel test 
 LIFETEST, PHREG – survival analysis  
 NPAR1WAY – Mann-Whitney U-test. 
Safety parameters  
Adverse events recorded during the study will be grouped into frequency tables by severity, 
seriousness and relationship with the study drug. 
Data presentation 
Descriptive statistics will be provided for each study continuous / interval variable. Numerical data 
will be presented by mean, standard deviation, min and max values. Relevant confidence intervals 
will also be provided for the data suggesting statistical conclusion. Extreme values (outliers) will 
be analyzed additionally. The data will be grouped by visits. The categorical variables will be 
presented as frequency tables by visits.